Our latest articles
Asco 2023 – liver tox casts a pall over Servier’s Indigo readout
Vorasidenib, potentially the first targeted therapy for low-grade glioma, comes at a toxicity price.
Asco 2023 – Pfizer pushes forward in drug-resistant breast cancer
While Ibrance has been bested by class rivals, Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance – though it is not alone.
Asco 2023 – Elevation follows in Astellas’s slipstream
There is reason for the enthusiasm behind Elevation’s anti-Claudin18.2 ADC, but no such good news for Zai Lab’s zolbetuximab challenger.
Asco 2023 – a role for immuno-oncology in ovarian cancer at last?
Astra’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
Asco 2023 – Novartis’s adjuvant breast cancer win comes with caveats
The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.
Quanterix sees a bright future for blood biomarkers
A new dawn breaks for blood tests in neurological diseases, though future data remain important.
Novo seeks a cardiovascular boost
An outcomes trial could increase demand for Wegovy even further – if pricing, and production, can be worked out.
Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Asco 2023 preview – Tigit lives again
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
Pfizer posts another haemophilia hit
The group is taking marstacimab to the regulators, but Novo’s MAb looks like a bad omen.
